HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

bexarotene (LGD1069)

a retinoid X receptor (RXR) selective agonist; structure in first source

Also Known As:

LGD1069; Targretin; 3-methyl-TTNEB; 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid; Elan brand of bexarotene; LG69 compound; LGD 1069; LGD-1069; Ligand brand of bexarotene

Networked: 324 relevant articles (59 outcomes, 84 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Duvic, Madeleine: 14 articles (08/2014 - 03/2002)
2.	Brown, Powel H: 13 articles (10/2012 - 05/2002)
3.	Lamph, William W: 13 articles (08/2011 - 05/2002)
4.	Lubet, Ronald A: 12 articles (12/2015 - 02/2005)
5.	Bissonnette, Reid P: 11 articles (10/2012 - 12/2004)
6.	Steele, Vernon E: 10 articles (12/2013 - 02/2005)
7.	Duvic, M: 8 articles (01/2014 - 11/2000)
8.	Rook, Alain H: 8 articles (09/2008 - 12/2002)
9.	Grubbs, Clinton J: 7 articles (06/2014 - 02/2005)
10.	Yen, Wan-Ching: 7 articles (05/2007 - 11/2004)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2006 - "In the prevention studies, in which the agents were administered beginning 5 days after MNU until the end of the study, targretin (150 mg/kg diet) and 4-methyl-UAB30 (200 mg/kg diet) were highly effective in decreasing cancer numbers by 75-85%. " 04/15/2005 - "In mouse mammary tumor virus-erbB2 mice treated with LGD1069, there was a marked decrease of COX-2 expression in both normal and malignant mammary tissues. " 05/01/2007 - "This suggests that bexarotene may have clinical utility in cancers where drug resistance by gene amplification is a major obstacle to successful therapy." 03/01/2008 - "Bexarotene has demonstrated chemopreventive and therapeutic efficacy towards mouse lung tumors. " 03/02/2006 - "Thus, bexarotene appears to be an effective preventive agent against lung tumor growth and progression."
2.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 04/01/2004 - "Since bexarotene has little bone marrow toxicity, it is an excellent candidate for combination therapy with other modalities useful in the treatment of cutaneous T-cell lymphoma. " 06/01/2004 - "Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene." 08/01/2006 - "Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies. " 05/01/2001 - "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results." 10/01/2003 - "In order to evaluate the efficacy of bexarotene in cutaneous T-cell lymphomas, a pilot trial was initiated. "
3.	Mycosis Fungoides 03/01/2003 - "Topical bexarotene is a novel synthetic rexinoid with few side-effects that has shown efficacy for treatment of mycosis fungoides skin lesions in recent Phase II-III clinical trials. " 01/01/2008 - "Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides." 01/01/2005 - "Because it was previously suggested that FMF may have a worse prognosis compared with classic mycosis fungoides, this impressive response to bexarotene is of great clinical interest and may spark new studies employing this novel retinoid for FMF treatment." 01/01/2015 - "The utility of bexarotene in mycosis fungoides and Sézary syndrome." 04/01/2014 - "[Granulomatous mycosis fungoides: combination therapy with bexarotene and PUVA]."
4.	Breast Neoplasms (Breast Cancer) 03/15/2003 - "The efficacy of bexarotene in patients with refractory metastatic breast cancer is limited. " 05/01/2005 - "The goal of this study was to evaluate the effect of bexarotene on development of acquired drug resistance and its role in overcoming acquired drug resistance in advanced breast cancer. " 03/15/2003 - "Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer." 12/01/2015 - "Taken together, our results demonstrate that UAB30 and Targretin each inhibit invasion and migration by targeting Src in human breast cancer cells. " 12/01/2015 - "We found that UAB30 or Targretin substantially inhibited invasiveness and migration of MCF-7 and SK-BR-3 human breast cancer cells. "
5.	Psoriasis (Pustulosis Palmaris et Plantaris) 07/01/2000 - "Plaque elevation was significantly reduced, and the severity of moderate to severe psoriasis was substantially improved in patients receiving oral bexarotene 0.5 to 2 mg/kg/day. " 05/01/2007 - "We report the results of a nonrandomized, open-label pilot trial investigating the safety, tolerability, and efficacy of bexarotene gel 1% in treating chronic mild to moderate plaque psoriasis. " 08/01/2004 - "Further studies are necessary to assess the optimal dose and the potential for bexarotene as a new therapy for psoriasis." 08/01/2004 - "In this phase II study we investigated the safety, tolerability, and effectiveness of bexarotene in psoriasis at doses of 0.5 to 3.0 mg/kg/day. " 07/01/2003 - "In 11 patients participating in a phase II study of oral bexarotene 0.5 mg/kg/day (7 patients) or 3.0 mg/kg/day (4 patients) for plaque-type psoriasis, MED tests were performed on uninvolved psoriatic skin on the lower back of the subjects before and after 12-week treatment. "

Related Drugs and Biologics

1.	bexarotene (LGD1069)
2.	Retinoid X Receptors (Retinoid X Receptor)
3.	Paclitaxel (Taxol)
4.	Tamoxifen
5.	Interferons
6.	methylurea
7.	Methylnitrosourea (N-Methyl-N-nitrosourea)
8.	Peptides
9.	erlotinib (CP 358,774)
10.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Chemoprevention
3.	Heterologous Transplantation (Xenotransplantation)
4.	Stem Cell Transplantation
5.	Remission Induction